The product, developed by Debiopharm for the treatment of acute esophageal variceal bleeding (EVB), is currently under review for approval by the Canadian Health Authorities.
In addition to purchasing the product directly from Debiopharm, Medical Futures is responsible for upfront and milestone payments.